{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:09:48Z","timestamp":1791828588880,"version":"4.3.4"},"reference-count":24,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019211","name":"AbbVie Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ACR Open Rheumatology"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Upadacitinib improved the signs and symptoms of non\u2010radiographic axial spondyloarthritis (nr\u2010axSpA) versus placebo over 14 weeks in the primary analysis of the SELECT\u2010AXIS 2 nr\u2010axSpA study. Here, we evaluated the efficacy and safety of upadacitinib through 1 year in patients with nr\u2010axSpA in SELECT\u2010AXIS 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients aged at least 18 years diagnosed with nr\u2010axSpA who fulfilled the 2009 Assessment of SpondyloArthritis International Society (ASAS) classification criteria and were receiving stable background therapy were randomized to upadacitinib 15 mg once daily or placebo for the 52\u2010week double\u2010blind period. Efficacy was assessed using non\u2010responder imputation incorporating multiple imputation (NRI\u2010MI) and as\u2010observed analyses for binary endpoints, and mixed\u2010effects model repeated measures for continuous endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 314 randomized patients, 259 (upadacitinib, n = 129; placebo, n = 130) completed 52 weeks of treatment. More patients receiving upadacitinib versus placebo achieved \u226540% improvement in ASAS at week 52 (63% vs 43%, NRI\u2010MI; nominal\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). Similar treatment effects were observed for the achievement of axSpA Disease Activity Score inactive disease (33% v 11%, NRI\u2010MI; nominal\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). Overall, patients receiving upadacitinib versus placebo showed greater improvement in disease activity, inflammation, pain, function, enthesitis, and quality of life through 52 weeks. Adverse events were generally comparable between the treatment groups. No opportunistic infections, malignancies, major adverse cardiovascular events, venous thromboembolic events, inflammatory bowel disease, or deaths were reported in those receiving upadacitinib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treatment with upadacitinib showed sustained efficacy versus placebo with no new safety findings identified through 1 year. These results support the continued favorable benefit\u2013risk profile of upadacitinib treatment for nr\u2010axSpA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr2.11669","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T04:55:27Z","timestamp":1715748927000},"page":"470-480","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Upadacitinib in Active Non\u2010radiographic Axial Spondyloarthritis:\n                    <scp>1\u2010Year<\/scp>\n                    Data From a\n                    <scp>Double\u2010Blind<\/scp>\n                    , Randomized,\n                    <scp>Placebo\u2010Controlled<\/scp>\n                    , Phase 3 Trial"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5932","authenticated-orcid":false,"given":"Filip","family":"Van den Bosch","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Pediatrics Ghent University, VIB Center for Inflammation Research  Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Division of Arthritis &amp; Rheumatic Diseases Oregon Health &amp; Science University  Portland Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-6015","authenticated-orcid":false,"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Infectious Diseases and Rheumatology Charit\u00e9 Universit\u00e4tsmedizin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-1755","authenticated-orcid":false,"given":"Walter P.","family":"Maksymowych","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Alberta  Edmonton Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Leiden University Medical Center  Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3542-2276","authenticated-orcid":false,"given":"Tae\u2010Hwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Hanyang University Hospital for Rheumatic Diseases  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-1589","authenticated-orcid":false,"given":"Mitsumasa","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology Kyorin University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet Herne, Ruhr\u2010University Bochum  Herne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Li","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8370-4166","authenticated-orcid":false,"given":"Kristin","family":"D'Silva","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wung","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u2010Ho","family":"Song","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221035"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001108"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1477591"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31591-4"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41042"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"issue":"2","key":"e_1_2_7_9_1","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002280","article-title":"Upadacitinib in active ankylosing spondylitis: results of the 2\u2010year, double\u2010blind, placebo\u2010controlled SELECT\u2010AXIS 1 study and open\u2010label extension","volume":"8","author":"Heijde D","year":"2022","journal-title":"RMD Open"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01212-0"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222608"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"e_1_2_7_13_1","volume":"21","author":"Garrett S, Jenkinson T, Kennedy LG","journal-title":"J Rheumatol"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225185"},{"issue":"2","key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","article-title":"The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68","author":"Sieper J","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138594"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32971-X"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41477"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40866"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190008"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab774"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203201"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219601"}],"container-title":["ACR Open Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11669","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:41:59Z","timestamp":1759416119000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr2.11669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1002\/acr2.11669"],"URL":"https:\/\/doi.org\/10.1002\/acr2.11669","archive":["Portico"],"relation":{},"ISSN":["2578-5745","2578-5745"],"issn-type":[{"value":"2578-5745","type":"print"},{"value":"2578-5745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]},"assertion":[{"value":"2023-12-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}